Benralizumab in the Treatment of Patients With Severe Asthma With ABPA
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
Phase IV, open-label study will evaluate effects of Benralizumab in the treatment of severe
asthma in patients with allergic bronchopulmonary aspergillosis